Journal ArticleOPEN ACCESS

Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)

  • Kim T
  • Ock C
  • Kim M
  • et al.
Annals of Oncology (2019) 30 v628
DOI: 10.1093/annonc/mdz260.051
N/ACitations
Citations of this article
32Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The NCI Common Terminology Criteria for Adverse Events v3.0 is a descriptive terminology which can be utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term.

Cite

CITATION STYLE

APA

Kim, T. M., Ock, C.-Y., Kim, M., Kim, S. H., Keam, B., Kim, Y. J., … Heo, D. S. (2019). Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19). Annals of Oncology, 30, v628. https://doi.org/10.1093/annonc/mdz260.051

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free